Shopping Cart 0
Cart Subtotal
USD 0

CorMedix Inc (CRMD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

CorMedix Inc (CorMedix) is a commercial-stage pharmaceutical company that develops and commercializes therapeutic products for prevention and treatment of cardiac, renal and infectious diseases. The company offers neutrolin, a non-antibiotic anti-infective developed as a preventative solution to decrease the threat of infection and blood clots in central venous catheters (CVCs). It offers neutrolin product, which act as novel formulation of taurolidine, citrate and heparin provides preventative solution by decreasing the triple threat of infection. CorMedix also develops therapeutic products for the prevention and treatment of inflammatory diseases. The company markets its products through its distribution network located across the US. CorMedix is headquartered in Berkeley Heights, New Jersey, the US.

CorMedix Inc (CRMD)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

CorMedix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

CorMedix Inc, Medical Devices Deals, 2012 to YTD 2018 10

CorMedix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

CorMedix Inc, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

CorMedix Enters into Co-Development Agreement with POETIC for CRMD-005 12

Licensing Agreements 13

CorMedix Enters into Licensing Agreement with NanoProteagen 13

Equity Offering 14

Cormedix to Raise USD15.61 Million in Public Offering of Shares 14

CorMedix Files Registration Statement for Public Offering of Shares for up to USD70 Million 15

CorMedix Plans to Raise up to USD20 Million in Public Offering of Shares 16

CorMedix to Raise USD5 Million in Private Placement of Preferred Shares 17

CorMedix Raises USD14 Million in Public Offering of Shares and Warrants 18

CorMedix Raises USD28.45 Million in Public Offering of Shares 20

CorMedix Completes Private Placement Of Units For USD 7.4 Million 21

CorMedix Completes Private Placement Of Shares For USD 1.5 Million 22

CorMedix Completes Private Placement Of Shares For USD 1.5 Million 24

CorMedix Announces Private Placement Of Shares For USD 2 Million 26

CorMedix Files Registration Statement For Public Offering Of Securities For USD 30 Million 27

Debt Offering 28

CorMedix Completes Final Tranche Of Private Placement Of Notes For USD 0.5 Million 28

CorMedix Inc-Key Competitors 29

CorMedix Inc-Key Employees 30

CorMedix Inc-Locations And Subsidiaries 31

Head Office 31

Other Locations & Subsidiaries 31

Recent Developments 32

Financial Announcements 32

Aug 14, 2018: Cormedix reports second quarter financial results 32

May 15, 2018: Cormedix Announces First Quarter 2018 Financial Results 33

Mar 19, 2018: Cormedix Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Business Update 34

Nov 09, 2017: CorMedix Reports Third Quarter Financial Results and Provides Business Update 36

Aug 09, 2017: CorMedix Reports Second Quarter Financial Results and Provides Business Update 38

May 10, 2017: CorMedix Reports First Quarter Financial Results and Provides Business Update 40

Mar 17, 2017: Cormedix Reports fourth quarter and full year 2016 financial results and provides business update 41

Corporate Communications 42

Aug 31, 2018: CorMedix announces NYSE american acceptance of plan to regain listing compliance 42

Aug 25, 2017: CorMedix Announces a Change to its Senior Leadership 43

Aug 07, 2017: CorMedix Appoints Gary Gelbfish, M.D., to Board of Directors 44

Jun 26, 2017: Cormedix Appoints Mehmood Khan, M.D. And Steven Lefkowitz to its Board of Directors 45

Jun 12, 2017: Cormedix Announces Changes to Board of Directors 47

Mar 02, 2017: Cormedix Appoints John L. Armstrong to Senior Leadership Team 48

Feb 01, 2017: Cormedix Announces New Appointments to Senior Leadership Team 49

Product News 50

09/07/2017: CorMedix Presents Data Demonstrating Antimicrobial Activity of Taurolidine Against Potentially Deadly Fungal Pathogen Candida auris 50

Other Significant Developments 51

Feb 27, 2018: Cormedix provides update on its financing plans in connection with its ongoing lock-it 100 clinical study 51

Appendix 52

Methodology 52

About GlobalData 52

Contact Us 52

Disclaimer 52


List Of Figure

List of Figures

CorMedix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

CorMedix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

CorMedix Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

CorMedix Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

CorMedix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

CorMedix Inc, Deals By Therapy Area, 2012 to YTD 2018 9

CorMedix Inc, Medical Devices Deals, 2012 to YTD 2018 10

CorMedix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

CorMedix Enters into Co-Development Agreement with POETIC for CRMD-005 12

CorMedix Enters into Licensing Agreement with NanoProteagen 13

Cormedix to Raise USD15.61 Million in Public Offering of Shares 14

CorMedix Files Registration Statement for Public Offering of Shares for up to USD70 Million 15

CorMedix Plans to Raise up to USD20 Million in Public Offering of Shares 16

CorMedix to Raise USD5 Million in Private Placement of Preferred Shares 17

CorMedix Raises USD14 Million in Public Offering of Shares and Warrants 18

CorMedix Raises USD28.45 Million in Public Offering of Shares 20

CorMedix Completes Private Placement Of Units For USD 7.4 Million 21

CorMedix Completes Private Placement Of Shares For USD 1.5 Million 22

CorMedix Completes Private Placement Of Shares For USD 1.5 Million 24

CorMedix Announces Private Placement Of Shares For USD 2 Million 26

CorMedix Files Registration Statement For Public Offering Of Securities For USD 30 Million 27

CorMedix Completes Final Tranche Of Private Placement Of Notes For USD 0.5 Million 28

CorMedix Inc, Key Competitors 29

CorMedix Inc, Key Employees 30

CorMedix Inc, Subsidiaries 31

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

CorMedix Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

CorMedix Inc (CorMedix) is a commercial-stage pharmaceutical company that develops and commercializes therapeutic products for prevention and treatment of cardiac, renal and infectious diseases. The company offers neutrolin, a non-antibiotic anti-infective developed as a preventative solution to decrease the threat of infection and blood clots in central venous catheters (CVCs). It offers neutrolin product, which act as novel formulation of taurolidine, citrate and heparin provides preventative solution by decreasing the triple threat of infection. CorMedix also develops therapeutic products for the prevention and treatment of inflammatory diseases. The company markets its products through its distribution network located across the US. CorMedix is headquartered in Berkeley Heights, New Jersey, the US.

CorMedix Inc (CRMD)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

CorMedix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

CorMedix Inc, Medical Devices Deals, 2012 to YTD 2018 10

CorMedix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

CorMedix Inc, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

CorMedix Enters into Co-Development Agreement with POETIC for CRMD-005 12

Licensing Agreements 13

CorMedix Enters into Licensing Agreement with NanoProteagen 13

Equity Offering 14

Cormedix to Raise USD15.61 Million in Public Offering of Shares 14

CorMedix Files Registration Statement for Public Offering of Shares for up to USD70 Million 15

CorMedix Plans to Raise up to USD20 Million in Public Offering of Shares 16

CorMedix to Raise USD5 Million in Private Placement of Preferred Shares 17

CorMedix Raises USD14 Million in Public Offering of Shares and Warrants 18

CorMedix Raises USD28.45 Million in Public Offering of Shares 20

CorMedix Completes Private Placement Of Units For USD 7.4 Million 21

CorMedix Completes Private Placement Of Shares For USD 1.5 Million 22

CorMedix Completes Private Placement Of Shares For USD 1.5 Million 24

CorMedix Announces Private Placement Of Shares For USD 2 Million 26

CorMedix Files Registration Statement For Public Offering Of Securities For USD 30 Million 27

Debt Offering 28

CorMedix Completes Final Tranche Of Private Placement Of Notes For USD 0.5 Million 28

CorMedix Inc-Key Competitors 29

CorMedix Inc-Key Employees 30

CorMedix Inc-Locations And Subsidiaries 31

Head Office 31

Other Locations & Subsidiaries 31

Recent Developments 32

Financial Announcements 32

Aug 14, 2018: Cormedix reports second quarter financial results 32

May 15, 2018: Cormedix Announces First Quarter 2018 Financial Results 33

Mar 19, 2018: Cormedix Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Business Update 34

Nov 09, 2017: CorMedix Reports Third Quarter Financial Results and Provides Business Update 36

Aug 09, 2017: CorMedix Reports Second Quarter Financial Results and Provides Business Update 38

May 10, 2017: CorMedix Reports First Quarter Financial Results and Provides Business Update 40

Mar 17, 2017: Cormedix Reports fourth quarter and full year 2016 financial results and provides business update 41

Corporate Communications 42

Aug 31, 2018: CorMedix announces NYSE american acceptance of plan to regain listing compliance 42

Aug 25, 2017: CorMedix Announces a Change to its Senior Leadership 43

Aug 07, 2017: CorMedix Appoints Gary Gelbfish, M.D., to Board of Directors 44

Jun 26, 2017: Cormedix Appoints Mehmood Khan, M.D. And Steven Lefkowitz to its Board of Directors 45

Jun 12, 2017: Cormedix Announces Changes to Board of Directors 47

Mar 02, 2017: Cormedix Appoints John L. Armstrong to Senior Leadership Team 48

Feb 01, 2017: Cormedix Announces New Appointments to Senior Leadership Team 49

Product News 50

09/07/2017: CorMedix Presents Data Demonstrating Antimicrobial Activity of Taurolidine Against Potentially Deadly Fungal Pathogen Candida auris 50

Other Significant Developments 51

Feb 27, 2018: Cormedix provides update on its financing plans in connection with its ongoing lock-it 100 clinical study 51

Appendix 52

Methodology 52

About GlobalData 52

Contact Us 52

Disclaimer 52


List Of Figure

List of Figures

CorMedix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

CorMedix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

CorMedix Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

CorMedix Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

CorMedix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

CorMedix Inc, Deals By Therapy Area, 2012 to YTD 2018 9

CorMedix Inc, Medical Devices Deals, 2012 to YTD 2018 10

CorMedix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

CorMedix Enters into Co-Development Agreement with POETIC for CRMD-005 12

CorMedix Enters into Licensing Agreement with NanoProteagen 13

Cormedix to Raise USD15.61 Million in Public Offering of Shares 14

CorMedix Files Registration Statement for Public Offering of Shares for up to USD70 Million 15

CorMedix Plans to Raise up to USD20 Million in Public Offering of Shares 16

CorMedix to Raise USD5 Million in Private Placement of Preferred Shares 17

CorMedix Raises USD14 Million in Public Offering of Shares and Warrants 18

CorMedix Raises USD28.45 Million in Public Offering of Shares 20

CorMedix Completes Private Placement Of Units For USD 7.4 Million 21

CorMedix Completes Private Placement Of Shares For USD 1.5 Million 22

CorMedix Completes Private Placement Of Shares For USD 1.5 Million 24

CorMedix Announces Private Placement Of Shares For USD 2 Million 26

CorMedix Files Registration Statement For Public Offering Of Securities For USD 30 Million 27

CorMedix Completes Final Tranche Of Private Placement Of Notes For USD 0.5 Million 28

CorMedix Inc, Key Competitors 29

CorMedix Inc, Key Employees 30

CorMedix Inc, Subsidiaries 31

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

CorMedix Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.